Huons plans to absorb its wholly-owned subsidiary, Huons Life Science, in a merger. The company is moving forward with the process, relying solely on board approval without holding a separate shareholders' meeting.
On May 22, Huons announced that its board of directors had completed the resolution for the small-scale merger with Huons Life Science. During the period for shareholders to express dissent, only 59,403 shares were opposed, representing about 0.5% of the total issued shares. This falls below the 20% threshold required by law to block a small-scale merger, allowing the board's approval to substitute for a shareholders' meeting.
The merger involves Huons absorbing its 100% owned subsidiary without issuing new shares, resulting in a merger ratio of 1 to 0. Under the small-scale merger procedure, shareholders will not be granted the right to request stock buybacks, and there will be no dilution of existing shareholders' stakes.
Market analysts interpret this announcement as more than just a simple consolidation of subsidiaries. Typically, the absorption of a wholly-owned subsidiary aims to eliminate redundant costs, unify research and development and business organizations, and simplify governance structures.
The final merger date is set for June 23.
Huons had previously disclosed its plan for the small-scale merger on April 22.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.